Product Description: Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects[1][2].
Applications: Cancer-Kinase/protease
Formula: C30H30FN7O6
References: [1]Xu X, et al. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Mol Cancer Ther. 2016 Nov;15(11):2586-2597./[2]Yan X, et al. Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. J Cancer Res Clin Oncol. 2018;144(4):697-706.
CAS Number: 1557268-88-8
Molecular Weight: 603.60
Compound Purity: 99.86
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;Btk;EGFR
Deutsch
English
